Mohammad AskarPublic working copy · medical review pending

Intermediate uveitis · 228

Intermediate uveitis

Vitreous-predominant inflammation that is defined by its anatomical site, often presents with floaters in a quiet eye, and is diagnosed late.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Define intermediate uveitis by its primary vitreous site, reserve pars planitis for snowball or snowbank disease without an associated cause, test selectively, and keep every original percentage tied to its unverified source.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Define the entity, pars planitis and the anatomy

Intermediate uveitis is defined by inflammation predominantly in the vitreous. Peripheral retinal or pars-plana findings can accompany it, but do not replace the primary vitreous site. SUN terminology and research classification facilitate reporting; research criteria are not a stand-alone clinical diagnostic test. 3

Snowballs are white aggregates of cells floating in the vitreous, usually inferiorly. Snowbanking is a confluent whitish exudate over the inferior pars plana. Both signs are typical, but neither is obligatory, and neither is pathognomonic of intermediate uveitis. 1 3

Pars planitis is the term for intermediate uveitis with snowballs or snowbanking when no associated infection or systemic disease is found. Idiopathic intermediate uveitis without these signs is therefore not automatically pars planitis. 1 3

The pars plana is the flat posterior part of the ciliary body, between the pars plicata and the ora serrata. The original lecture described it as a 5-6 mm band between the whole ciliary body and the neurosensory retina; that location is inaccurate and the width is a variable, unverified figure. 1

Original cohort figures place intermediate uveitis at 5-15% of non-infectious uveitis, with onset usually at 20-40 years and a slight female predominance (about 1.2:1). Bilateral disease was reported in 50-80% and unilateral disease in 20-50%, often asymmetrically, with a diagnostic delay of 3-6 months. Denominators and populations are not traced here. 1

02Separate idiopathic disease, MS, sarcoidosis, TB, IBD and other causes

Idiopathic intermediate uveitis is the largest group in the original lecture, at 50-70% of cases, and is diagnosed only after known systemic and infectious causes are excluded. The source debated genetic predisposition against environmental factors because of regional clustering; that debate remains unresolved. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

Multiple sclerosis is the second most commonly reported association, at 10-20%, and the source proposed a shared TH17-mediated mechanism. Intermediate uveitis can be the first clinical sign of MS, so neurology should be involved when the history or examination suggests it, including before anti-TNF therapy. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

Sarcoidosis was reported in 5-10% and is characterised by non-caseating granulomas, not by non-calcifying granulomas. It can involve lung, eyes, skin, lymph nodes, heart, liver, joints, bones, kidneys and brain, so tests should follow symptoms and findings rather than a fixed list. Sarcoid-associated uveitis is often more severe and more steroid-dependent than idiopathic disease. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

The original claimed that about 2 billion people have latent TB and that 1% of them develop intermediate uveitis, without denominators, time frame or diagnostic standard; this is recorded as an unsupported number and does not mean that latent TB causes 1% of uveitis. 1 4

The same lecture's 10-50 fold reactivation risk with anti-TNF therapy lacked agent and exposure context. IGRA indicates infection or sensitisation, not ocular causation, and an original 50-80% PCR positivity rate is not universal; a negative PCR cannot exclude TB. 1 4

Inflammatory bowel disease was present in about 5-10% of the original patients, and Crohn disease was reported more often than ulcerative colitis; this is observational association rather than proof of a shared mechanism. HLA-B27 is a weaker association than in anterior uveitis and should be considered mainly when joint symptoms are present. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

Other reported infectious causes include herpes viruses, syphilis, Lyme borreliosis, toxoplasmosis and histoplasmosis, and CMV is relevant in immunosuppressed patients. Syphilis remains the great imitator and is tested according to phenotype and risk, not as a substitute for clinical judgement. 1

03Examine the peripheral retina and image complications

Floaters were reported by 80-90% of the original patients and blurred vision by about 50%, the latter often caused by CME or cataract rather than by the vitreitis itself. Photopsias may occur, the eye is typically white and painless, and anterior chamber cells are minimal or absent, which explains the diagnostic delay. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

Slit-lamp examination usually shows a quiet conjunctiva, a clear cornea and few or no anterior chamber cells. Keratic precipitates are possible in sarcoidosis or TB. Intraocular pressure is most often normal; it may rise with trabeculitis or a steroid response and fall with ciliary body shutdown. 1

Record vitreous cells and haze separately using an appropriate documented grading method; do not infer a validated SUN vitreous-cell scale from this export. The lecturer’s personal disc-visibility scale is not validated here. Peripheral phlebitis, disc swelling and vascular sheathing may accompany vitreous inflammation. 1 3

After pupillary dilation, indirect ophthalmoscopy with a 20D or 22D lens is indispensable for assessing the peripheral retina and pars plana. Direct examination alone can miss peripheral snowbanks and detachment. 1

OCT mainly detects and monitors CME. Fluorescein angiography, preferably wide-field, shows peripheral vascular leakage and disc leakage; OCT angiography shows flow without dye and therefore does not demonstrate leakage. B-scan ultrasound is indicated when dense media opacity prevents fundus view, for example to exclude retinal detachment. 1

The source proposed chest imaging, ACE, an IGRA and syphilis serology as a basic panel, with HLA-B27 for joint symptoms, MRI for neurological symptoms, HRCT for strong TB suspicion and CMV testing in immunosuppression. Targeted chest imaging and a sarcoid workup are appropriate in pars planitis, but no universal mandatory blood panel is established, and a normal chest radiograph does not universally exclude sarcoidosis. 1 4

The original ACE specificity of 96% and sensitivity of 40–50% lack a traced population and decision threshold. ACE is not a diagnostic proof of ocular sarcoidosis; interpret it with clinical and systemic findings rather than using a normal value to exclude disease. 1 3

04Recognise complications and interpret prognosis

CME is the most common complication in the original series, at about 40%, and was attributed to pro-inflammatory cytokines and VEGF. Cataract is very common, from chronic inflammation or long-term steroids, and secondary glaucoma occurs in about 15%, through trabeculitis or steroid-induced pressure rise. Posterior synechiae are less frequent than in anterior uveitis but still possible, and hypotony can follow severe ciliary body inflammation. These original frequencies have no traced cohort denominator here and are not general population estimates. 1

Rarer complications listed in the source are epiretinal membrane, retinal detachment, vitreous haemorrhage, optic neuritis and band keratopathy. Each changes follow-up and treatment, so a quiet anterior segment must not end the examination. 1

The original reported that 60-80% of patients retain 20/40 or better, while its summary table wrote more than 20/40; the two statements are not identical and neither is a verified population outcome. Spontaneous remission is possible, but many patients develop complications because diagnosis is delayed. 1

Five-year remission under therapy was reported as about 78% in children and about 60% in adults, so a paediatric onset was not universally better in every respect. Remission while on therapy is distinct from drug-free remission, and the figures are unverified cohort estimates rather than individual prognoses. 1

05Treat by severity and keep drug roles distinct

The original proposes observation for mild disease without visual loss or complications, with review every 4–6 weeks; this is not a universally verified interval. Increasing vitreous inflammation, CME or visual loss changes management. Its estimate that 25–30% need no medication is also unverified. 1

Topical steroids and NSAIDs act mainly on associated anterior segment activity; they are not monotherapy for vitreous inflammation or for CME alone. Their posterior penetration is limited, so a quiet anterior chamber does not mean the eye is controlled. 1

Periocular or sub-Tenon steroid injections, for example triamcinolone, and intravitreal steroids deliver higher posterior concentrations. They carry risks of intraocular pressure rise, cataract and infection, including endophthalmitis after injection, and their effect is time-limited. 1

Oral prednisolone at 0.5-1 mg/kg/day is an illustrative specialist regimen from the source for significant inflammation, CME or bilateral disease, not an individual prescription. Tapering must be slow, and calcium with vitamin D and gastric protection are risk-based measures rather than automatic for every patient. 1

Methotrexate, azathioprine and mycophenolate are used for steroid dependence, intolerance or relapsing disease; the original's threshold above 10 mg prednisolone per day is a context, not a universal cutoff. Onset of 6-12 weeks is variable, and laboratory monitoring is required. 1

Adalimumab (Humira) is a fully human monoclonal anti-TNF antibody with an approved uveitis indication, but not every TNF inhibitor shares that approval. Infliximab (Remicade) and tocilizumab have different and partly off-label contexts in uveitis, and the source's claim of a securely faster onset for infliximab is not established as universal superiority. 1 4

Active and latent TB must be evaluated before starting anti-TNF therapy, and active TB or another severe infection is a contraindication. In intermediate uveitis a neurological evaluation is advised before and during treatment, without implying MRI for every patient. Methotrexate is not an automatic safe alternative, because infection control comes first and any immunosuppression is chosen jointly with the treating specialists. 4 1

The fluocinolone implant (Retisert) and the dexamethasone implant (Ozurdex) are different products with different approvals, jurisdictions and durations; the source's 3-6 month effect estimate is variable. Both carry pressure, cataract and infection risks. A topical steroid-response challenge is not a validated safety screen, and a negative challenge cannot exclude a later implant response. 1

Pars plana vitrectomy, cryotherapy and laser are reserved for selected non-clearing vitreous opacity or complications such as retinal detachment or epiretinal membrane. The original ladder implies a sequence that the source does not test, so surgery is a clinical decision rather than a proven final rung. 1

Treat by severity and keep drug roles distinct
Treatment levelApproachIndications and notes
Stage 1: observationOriginal 4–6-week review proposal; individualiseMild disease without visual loss or complications; start treatment if vitreitis increases, CME appears or vision falls. The original 25-30% needing no medication is unverified.
Stage 2: local therapyPeriocular or sub-Tenon steroid injection (e.g. triamcinolone); topical steroids or NSAIDsInjections act locally but carry pressure rise, cataract and infection risk; topical drops have limited posterior effect and mainly treat associated anterior activity.
Stage 3: systemic first-lineOral corticosteroids (e.g. prednisolone 0.5-1 mg/kg/day)Significant inflammation, CME or bilateral disease; slow taper. Calcium and vitamin D and gastric protection are risk-based, not automatic for everyone.
Stage 4: immunosuppressionMethotrexate, azathioprine, mycophenolateSteroid dependence (the original's above 10 mg prednisolone per day is a context, not a universal cutoff), intolerance or relapses; onset 6-12 weeks with laboratory monitoring.
Stage 5: biologicsAdalimumab (Humira), infliximab (Remicade), others (e.g. tocilizumab)Refractory disease; evaluate active and latent TB before anti-TNF. Not every TNF inhibitor shares the same approved indication, and no universal faster onset is proven.
Intravitreal therapyDexamethasone implant (Ozurdex), fluocinolone implant (Retisert)Effective for CME with pressure, cataract and infection risk; the 3-6 month effect estimate is variable, products and jurisdictions differ, and a steroid-response challenge is not a validated safety screen.
Surgical interventionPars plana vitrectomy, cryotherapy or laserReserved for severe non-clearing vitreous opacity or complications such as retinal detachment or epiretinal membrane; not proof of a systematic ladder.
Treat by severity and keep drug roles distinct
AspectKey information
DefinitionPredominantly vitreous inflammation; peripheral retinal or pars-plana signs may accompany it.
Main signsSnowballs (vitreous aggregates) and snowbanking (exudate over the inferior pars plana); typical but not pathognomonic.
SymptomsFloaters (often), blurred vision, photopsias; usually a white and painless eye.
Common aetiologiesIdiopathic 50-70%; MS 10-20%; sarcoidosis 5-10%; TB; IBD 5-10%. Original unverified cohort figures.
Basic diagnosticsDilated peripheral examination; targeted chest imaging, ACE, IGRA and syphilis serology; no universally mandatory panel.
Most common complicationCME about 40%, cataract, secondary glaucoma about 15%. Original figures are unverified cohort estimates.
Treatment levelsObservation; local or systemic steroids; immunosuppressants; biologics; implants or surgery for selected cases.
PrognosisGenerally good; 60-80% retain above 20/40 with timely treatment. The original table's above 20/40 is not identical to 20/40 or better. Original figures are unverified cohort estimates.

06Work through the three teaching cases

Case 1: a 28-year-old woman with bilateral intermediate uveitis. After initial stabilisation with steroids, the recommended strategy was steroid tapering with continued methotrexate as long-term therapy. 1

Case 2: a 35-year-old man who did not respond to methotrexate and azathioprine and was switched to adalimumab. The original figure of about 48% relapse in the first year after stopping adalimumab is an unverified population estimate, not this patient's personal risk, so stopping remains an individual decision. 1

Case 3: a child with uveitis and proven active TB. Anti-TNF therapy is contraindicated during active TB, but methotrexate is not an automatic safer option and not an immediate substitute; the infection is treated with the appropriate specialists, and any immunosuppression is selected jointly after infection assessment. 1 4

07Monitor, taper and counsel

Each visit checks vitreous cells and haze, CME on OCT, intraocular pressure during steroid treatment, cataract and adherence to immunosuppression with its laboratory monitoring. Follow-up intervals are individualised by activity, complications and treatment rather than by a fixed timetable. 1

Remission on therapy and drug-free remission are different states, and tapering is slow enough to detect relapse. Patients should understand that stopping a biologic or steroid-sparing agent is a shared decision, not a fixed milestone. 1

New floaters, rapid visual loss, pain, marked inflammation or neurological symptoms need urgent review, and suspected infection during immunosuppression is an emergency. These warnings belong in the patient conversation, not only in the record. 1

What are the main learning points of the intermediate uveitis lecture?

Predominantly vitreous inflammation; pars planitis requires snowballs or snowbanks without an associated cause. Test selectively for MS, sarcoidosis and TB; treat by severity and preserve original percentages as unverified claims.

Which findings require urgent assessment?

New floaters, blurred vision, macular oedema, pain, marked inflammation or suspected infection or neurological disease.

References and access status

  1. 1
    Immutable original export; intermediate uveitis export

    Complete export read; speaker attribution (Dr. Samir Hussein), recording and percentages not independently verified.

  2. 2
    Historical evidence pages of reviews 134, 144 and 219

    Partial reuse only from the evidence pages of reviews 134-uveitis-endophthalmitis, 144-uveitis-diagnosis-imaging (linked) and 219-paediatric-uveitis-masquerades; not exact equivalents and no fresh source verification.

  3. 3
    SUN classification criteria for pars planitis; PMC8634775

    Parent read the selected introduction, Table 3 and the classification-versus-diagnostic discussion on 18 November 2026; not the whole article or images. SUN research criteria are not a universal clinical diagnostic test; pars planitis criteria exclude associated MS, sarcoidosis, syphilis and appropriate Lyme testing, and the reported epidemiology is observational and variable.

  4. 4
    EMA Humira product information

    Parent read the selected indexed contraindication, infection and tuberculosis sections 4.3-4.4 and the neurological warning text on 18 November 2026; not the whole SmPC. Active TB and severe infection are contraindicated, active and latent TB must be evaluated before starting, and neurological evaluation is advised in intermediate uveitis before and during treatment without inferring MRI for every patient.

Original lecture link